Icotinib alone or with bevacizumab as first-line therapy in Chinese patients with advanced nonsquamous non-small cell lung cancer and activating EGFR mutations: A retrospective study,Thoracic Cancer

当前位置： X-MOL 学术 › Thorac. Cancer › 论文详情

Our official English website, www.x-mol.net, welcomes your feedback! (Note: you will need to create a separate account there.)

Icotinib alone or with bevacizumab as first-line therapy in Chinese patients with advanced nonsquamous non-small cell lung cancer and activating EGFR mutations: A retrospective study
Thoracic Cancer ( IF 2.3 ) Pub Date : 2021-07-13 , DOI: 10.1111/1759-7714.14079
Zhansheng Jiang _{1,

2,

3} , Jing Zhang _{1,

2,

3} , Haiyan Sun _{1,

2,

3} , Cong Wang _{1,

2,

3} , Yu Zhang _{1,

2,

3} , Yanyang Li _{1,

2,

3} , Zhanyu Pan _{1,

2,

3}

Affiliation

This study focused on comparing the safety and therapeutic effects between icotinib monotherapy and icotinib plus bevacizumab combined therapy in non-small cell lung cancer (NSCLC) cases harboring EGFR mutations.

更新日期：2021-09-02

点击分享查看原文

点击收藏

公开下载

阅读更多本刊最新论文本刊介绍/投稿指南11